We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

BTT-1023 in Rheumatoid Arthritis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00851240
First Posted: February 25, 2009
Last Update Posted: February 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Biotie Therapies Corp.
  Purpose
Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.

Condition Intervention Phase
Rheumatoid Arthritis Drug: BTT-1023 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Rheumatoid Arthritis - a Double-blind Randomized Placebo-controlled Sequential Group Trial

Resource links provided by NLM:


Further study details as provided by Biotie Therapies Corp.:

Primary Outcome Measures:
  • Incidence and intensity of adverse events [ Time Frame: 17 wk ]

Secondary Outcome Measures:
  • Serum concentrations of the verum [ Time Frame: 17 wk ]
  • Disease activity [ Time Frame: 17 wk ]

Enrollment: 24
Study Start Date: February 2009
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BTT1023 Drug: BTT-1023
intravenous
Placebo Comparator: Placebo Drug: Placebo
Intravenous

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult-onset rheumatoid arthritis

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00851240


Locations
Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria, 1612
Sponsors and Collaborators
Biotie Therapies Corp.
Investigators
Study Director: Antero Kallio, MD Biotie Therapies Corp.
  More Information

Responsible Party: Biotie Therapies Corp.
ClinicalTrials.gov Identifier: NCT00851240     History of Changes
Other Study ID Numbers: BTT12-CD015
First Submitted: February 2, 2009
First Posted: February 25, 2009
Last Update Posted: February 3, 2012
Last Verified: February 2012

Keywords provided by Biotie Therapies Corp.:
rheumatoid arthritis
safety

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases